drugset / Trial / NCT05206877
Topical Insulin for Glaucoma
RandomizedSingle-groupSingle-blindTreatment
Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Timeline
- Start
- 2022-04-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | 4 iu | Topical |
| Subject | Insulin | Protein / enzyme biologic | 20 iu | Topical |